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ABSTRACT
Objective: To evaluate different doses of ivermectin in adult patients 
with mild COVID-19 and to evaluate the effect of ivermectin on 
mortality and clinical consequences.
Methods: A randomized, double-blind, placebo-controlled, 
multicenter clinical trial was performed at five hospitals. A total 
of 180 mild hospitalized patients with COVID-19 confirmed by 
PCR or chest image tests were enrolled and allocated to six arms 
including hydroxychloroquine 200 mg twice per day, placebo 
plus hydroxychloroquine 200 mg twice per day, single dose 
ivermectin (200 µg/kg), three low interval doses of ivermectin 
(200, 200, 200 µg/kg), single dose ivermectin (400 µg/kg), and 
three high interval doses of ivermectin (400, 200, 200 µg/kg). 
The primary endpoint of this trial was all-cause of mortality or 
clinical recovery. The radiographic findings, hospitalization and 
low O2 saturation duration, and hematological variables of blood 
samples were analyzed. 
Results: A total of 16.7% (5/30) and 20.0% (6/30) patients died 
in arms treated with hydroxychloroquine 200 mg twice per day 
and placebo plus hydroxychloroquine 200 mg twice per day, 
respectively, and a reduction in mortality rate in patients 
receiving ivermectin treatment to 0%, 10%, 0% and 3.3% for 
arms 1-4 were observed. Risk of mortality was also decreased 
about 15% in the ivermectin treated arms. 
Conclusions: Ivermectin as an adjunct reduces the rate of mortality, 
time of low O2 saturation, and duration of hospitalization in adult 
COVID-19 patients. The improvement of other clinical parameters 
shows that ivermectin, with a wide margin of safety, had a high 
therapeutic effect on COVID-19.
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1. Introduction
  The COVID-19 disease has become a pandemic after the WHO 
declaration in March 2020. This disease has created a difficult 
condition around the world, and hence there is an important 
and urgent need to find proper treatments for an effective cure, 
decrease the virus carriage duration, and thus limit its transmission 
in society[1-3]. So far, different drugs such as hydroxychloroquine, 
azithromycin, remdesivir, oseltamivir, lopinavir, and  ritonavir 
have been used against COVID-19[4-10]. However, among the 
candidate treatments, only remdesivir have been tested in large 
Asian Pacific Journal of Tropical Medicine 2021; 14(6): 266-273
Asian Pacific Journal of Tropical Medicine
apjtm.org
This is an open access journal, and articles are distributed under the terms of the 
Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which 
allows others to remix, tweak, and build upon the work non-commercially, as long 
as appropriate credit is given and the new creations are licensed under the identical 
terms.
For reprints contact: reprints@medknow.com
©2021 Asian Pacific Journal of Tropical Medicine Produced by Wolters Kluwer- 
Medknow. All rights reserved.
How to cite this article: Shakhsi Niaee M, Namdar P, Allami A, Zolghadr L, Javadi A, 
Karampour A, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-
19 patients: A randomized multi-center clinical trial. Asian Pac J Trop Med 2021; 
14(6): 266-273.
Original Article
To whom correspondence may be addressed. E-mail: gheibi_n@yahoo.com, 
ngheibi@qums.ac.ir
Article history: Received 12 December 2020           Revision 31 May 2021     
                             Accepted 4 June 2021                       Available online 25 June 2021
10.4103/1995-7645.318304
[Downloaded free from http://www.apjtm.org on Monday, September 13, 2021, IP: 10.232.74.26]
